TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21622693
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa (150 µg)
Study: 21623265
Drug: Crizotinib (PF02341066),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (PF02341066), a dual MET and ALK inhibitor; specific dosage and duration not mentioned.
Study: 21623649
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B12 (9 μg daily)
Study: 21627839
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus celecoxib (400 mg/day)
Study: 21628633
Drug: Phylloquinone supplementation
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone supplementation (500 μg/d) for 3 years
Study: 21632855
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy 30 days before tumor harvest
Study: 21633906
Drug: Bortezomib (a
Normalized name: bortezomib (as mannitol boronic ester)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (a 26S proteasome inhibitor)
Study: 21635145
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment in healthy volunteers
Study: 21639407
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) 20 mg, uptitrated to OM 40 mg, followed by hydrochlorothiazide (HCTZ) 12.5-25 mg at 3-week intervals
Study: 21642245
Drug: Adenoviral vector
Normalized name: Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12
DrugBank: Ad-RTS-hIL-12 (DB17177)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoviral vector encoding human IFN-α (Ad.IFN-α2b) administered intrapleurally, two doses.
Study: 21642514
Drug: Neoadjuvant trabectedin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant trabectedin (1.5 mg/m(2) 24-h i.v. infusion every 3 weeks; three to six cycles)
Study: 21642685
Drug: Imatinib mesylate,
Normalized name: Imatinib Mesylate, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib mesylate, 400 mg orally twice daily
Study: 21646032
Drug: Sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sapropterin dihydrochloride (Kuvan®) at a mean dose of 16.2±4.7 mg/kg/day for an average exposure of 658.7±221.3 days.
Study: 21648284
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) stimulation testing with arginine and GH releasing hormone
Study: 21649541
Drug: Enzastaurin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (250 mg twice daily)
Study: 21653689
Drug: Erlotinib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (125 mg/m²/day for children, 90 mg/m²/day for adults)
Study: 21657861
Drug: Subcutaneous methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous methylnaltrexone (0.15 mg/kg initial dose, adjusted to 0.3 mg/kg or 0.075 mg/kg as needed, maximum one dose per 24 hours)
Study: 21659356
Drug: Treosulfan (3×14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan (3×14 g/m²) and Fludarabine (5×30 mg/m²)
Study: 21659363
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m(2)/day intravenously over one hour for five consecutive days every four weeks
Study: 31375393
Drug: Decitabine treatment
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine treatment
Study: 21663862
Drug: Weekly topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly topotecan (6 mg/m(2) I.V. for 6 weeks)
Study: 21664608
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of drug use
Study: 21666249
Drug: Kidney injury
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney injury molecule 1 (KIM-1)
Study: 21666249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of impaired eGFR, increased UACR, and high NAG
Study: 21667134
Drug: Preoperative S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative S-1 (80 mg/m²/day, days 1-21) plus cisplatin (60 mg/m² on day 8) for 2 courses followed by radical gastrectomy and postoperative S-1 (80 mg/m²/day, days 1-14) every 3 weeks for 1 year
Study: 21668924
Drug: Dipeptidyl peptidase-4
Normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dipeptidyl peptidase-4 inhibitor sitagliptin
Study: 21670449
Drug: Imatinib 260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 260 mg/m² daily
Study: 21673350
Drug: Epratuzumab (E)
Normalized name: Vitamin E
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epratuzumab (E) 360 mg/m² intravenously with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for 6 cycles
Study: 21674178
Drug: Hyperglycaemia (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (18 mmol/l)
Study: 21674178
Drug: Hypoglycaemia (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (2.5 mmol/l) followed by hyperglycaemia (12 mmol/l) and another hypoglycaemia (3.0 mmol/l)
Study: 21675055
Drug: Erythropoietin (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (exact dosage and duration not specified)
Study: 21676217
Drug: Lapatinib 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1250 mg/day continuously and capecitabine 1000 mg/m2 twice daily on a 2-week-on and 1-week-off schedule
Study: 21676394
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol (35 μg) and norgestimate (0.18/0.215/0.25 mg) for 6 cycles
Study: 21676694
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (CBT)
Study: 21679735
Drug: Autologous dendritic-cell-based
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic-cell-based therapeutic HIV-1 vaccine
Study: 21680850
Drug: Aliskiren (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (oral direct renin inhibitor) for 12 months
Study: 21681115
Drug: 72-hour coefficient
Normalized name: ALUMINUM CHLOROHYDRATE 128 mg in 1 mL TOPICAL CREAM [Kiehls Since 1851 Superbly Efficient Antiperspirant and Deodorant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72-hour coefficient of fat absorption (CFA) measurement
Study: 21685540
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg EFV with RFN
Study: 21685540
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg EFV with RFN
Study: 21686825
Drug: Orthopaedic full
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthopaedic full spinal supports along with conventional treatment
Study: 21690557
Drug: Pomalidomide 2
Normalized name: pomalidomide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 2 mg/d with dexamethasone 40 mg weekly
Study: 21690557
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg/d with dexamethasone 40 mg weekly
Study: 21692673
Drug: Vaccination, antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination, antiviral strategies, and infection control measures
Study: 21692673
Drug: Antiviral therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapies
Study: 21692906
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIG) therapy
Study: 21693599
Drug: Activation of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activation of compound patterns (simplified letters)
Study: 21693599
Drug: Concurrent retinal
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent retinal stimulation
Study: 21696575
Drug: Vitamin D3-fortified
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3-fortified yogurt drink (FYD; 500 IU vitamin D/250 mL)
Study: 21697252
Drug: Lanreotide acetate
Normalized name: Lanreotide Acetate
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide acetate (Somatuline Autogel), 30 mg once a month, administered by deep subcutaneous injection.
Study: 21697252
Drug: Octreotide via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide via insulin pump (initial treatment).
Study: 21699130
Drug: Metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole gel 1%
Study: 21699369
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ezetimibe and 20 mg simvastatin once daily for 6 weeks
Study: 21699798
Drug: TG4040 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4040 vaccine (10⁶, 10⁷, or 10⁸ plaque-forming units) administered subcutaneously on days 1, 8, and 15.
Study: 21699798
Drug: TG4040 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4040 vaccine (10⁸ plaque-forming units) administered subcutaneously.
Study: 21699798
Drug: TG4040 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4040 vaccine (10⁸ plaque-forming units) with marked T-cell responses.
Study: 21700776
Drug: Decitabine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (0.2 mg/kg subcutaneous 2 times per week for 12 weeks)
Study: 21701566
Drug: Lowest two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest two quartiles of insulin sensitivity (S(I) <50th)
Study: 21701566
Drug: Most insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Most insulin sensitive (IS) individuals
Study: 21701566
Drug: Most insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Most insulin resistant (IR) individuals
Study: 21701566
Drug: Highest two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest two quartiles of insulin sensitivity (S(I) >50th)
Study: 21702914
Drug: Salvage docetaxel/cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage docetaxel/cisplatin chemotherapy
Study: 21711530
Drug: Parental group
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental group support therapy, online/offline website, pediatrician involvement, video simulation game ('Dr. Cruz'), personalized biochemical feedback on exposure levels.
Study: 21714878
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day ribavirin (group C) for 16 weeks
Study: 21714878
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day ribavirin (group D) for 16 weeks
Study: 21714878
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day ribavirin (group C) for 16 weeks with low viral load
Study: 21714878
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day ribavirin (group D) for 16 weeks with low viral load
Study: 21714878
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day ribavirin (group C) for 16 weeks with high viral load
Study: 21714878
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day ribavirin (group D) for 16 weeks with high viral load
Study: 21715509
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g yellow maize porridge containing 1.2 mg β-carotene, 20 g butter, and a 0.5-g corn oil capsule
Study: 21715509
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg [(13)C(10)]retinyl acetate in a 0.5-g corn oil capsule and 300 g white maize porridge with 20 g butter
Study: 21716260
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg paricalcitol, orally active vitamin D receptor activator, every morning for 7 days
Study: 21717386
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (5 or 10 mg) daily for 12 months
Study: 21719129
Drug: hsCRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP levels ≥2mg/L
Study: 21719129
Drug: hsCRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP levels <2mg/L
Study: 21719129
Drug: hsCRP, LDL-cholesterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP, LDL-cholesterol, BMI, and insulin resistance
Study: 21719884
Drug: Lenalidomide up
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide up to 30 mg daily for 16 weeks
Study: 21721925
Drug: Acupuncture treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment, twice a week for 6 weeks
Study: 21723591
Drug: Hemoglobin levels
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin levels below 14 g/dL
Study: 21723591
Drug: Hemoglobin levels
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin levels at or above 14 g/dL
Study: 21725050
Drug: Lenalidomide 5
Normalized name: lenalidomide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 5 mg daily for 56 days, then titrated up to 25 mg/d as tolerated
Study: 21725050
Drug: Lenalidomide therapy
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide therapy
Study: 21725056
Drug: Tipifarnib 300
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle
Study: 21729182
Drug: Inhaled dust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dust mite allergen challenge (Dermatophagoides farinae extract; PD(max) = fall in forced expiratory volume in 1 s of 10%)
Study: 21729182
Drug: Inhaled dust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dust mite allergen challenge
Study: 21732212
Drug: Monthly self-weighing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly self-weighing
Study: 21733227
Drug: OROS-MPH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-MPH treatment for 12 weeks
Study: 21738597
Drug: Five-drug combination
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug combination antiretroviral therapy (cART) including enfuvirtide for the first 6 months, optimized cART with three or more drugs for 12 months.
Study: 21740082
Drug: Bortezomib in
Normalized name: bortezomib Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib in combination with arsenic trioxide, sorafenib, and cytarabine
Study: 21740673
Drug: Empiric TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric TB treatment given to 8 (40%) patients
Study: 21741058
Drug: Rosiglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone treatment for 8 weeks
Study: 21742281
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) herbal concoctions taken orally for 24 weeks while continuing with Western medical management.
Study: 21742281
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) herbal concoctions
Study: 21744485
Drug: Hydroxyurea overdose
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea overdose (612 mg/kg body weight)
Study: 21745716
Drug: Standard antimalarial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antimalarial therapy
Study: 21748299
Drug: Figitumumab 20
Normalized name: Figitumumab
DrugBank: Figitumumab (DB11685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel
Study: 21748299
Drug: Figitumumab (6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin and paclitaxel
Study: 21749641
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) treatment
Study: 21749698
Drug: Mean dose
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean dose to whole breast
Study: 21752435
Drug: Temsirolimus 25mg
Normalized name: TEMSIROLIMUS 25MG/ML INJ,SOLN
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 25mg weekly IV until progression or intolerable toxicity
Study: 21752743
Drug: Diet, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet, oral antidiabetes agents, and/or injectables (insulin and/or GLP-1 analogues)
Study: 21752947
Drug: Vero cell
Normalized name: Vero Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero cell antirabies vaccine
Study: 21752947
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose after 5 years
Study: 21756035
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² days 1, 4, 8, 11, 45, 52), cyclophosphamide (50 mg/kg days 15-18), pegfilgrastim (day 20)
Study: 21763217
Drug: Mood-stabilizing medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood-stabilizing medications
Study: 21763653
Drug: Genous™ endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genous™ endothelial progenitor cell (EPC) capturing stent with statin therapy (HmG-CoA-reductase inhibitors)
Study: 21763653
Drug: Genous™ endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genous™ endothelial progenitor cell (EPC) capturing stent with statin therapy
Study: 21765864
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (depression treatment referrals and print information on diabetes management)
Study: 21767595
Drug: 15-μg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-μg dose of a monovalent, unadjuvanted inactivated 2009 H1N1 influenza vaccine
Study: 21769849
Drug: Imatinib (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (up to 600 mg/day)
Study: 21775510
Drug: Insulin-resistant women
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant women (C-ISI <4.6)
Study: 21775510
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (insulin-resistant and insulin-sensitive)
Study: 21784508
Drug: AVI-4658 (phosphorodiamidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVI-4658 (phosphorodiamidate morpholino oligomer) at doses of 0.5, 1.0, 2.0, 4.0, 10.0, and 20.0 mg/kg bodyweight
Study: 21784781
Drug: Aztreonam for
Normalized name: Aztreonam for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam for inhalation solution (AZLI) thrice daily (AZLI3)
Study: 21785475
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy continued during interventional techniques
Study: 21785475
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy discontinued prior to interventional techniques
Study: 21787417
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/day orally for 4 weeks on treatment, followed by 2 weeks off treatment
Study: 21788422
Drug: ASO3-adjuvanted pandemic
Normalized name: pangamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada), 0.5-mL dose
Study: 21789604
Drug: Self-collected swabs
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-collected swabs for high concentrations of A. vaginae (≥10^8 copies/mL)
Study: 21789604
Drug: Self-collected swabs
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-collected swabs for high concentrations of G. vaginalis (≥10^9 copies/mL)
Study: 21791058
Drug: Motesanib 100
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 100 mg QD + erlotinib (100 mg QD) + gemcitabine (1000 mg/m2)
Study: 21791058
Drug: Motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 125 mg QD + erlotinib (150 mg QD)
Study: 21791058
Drug: Motesanib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib (50 mg QD, 75 mg BID, 125 mg QD, or 100 mg QD) + erlotinib (100 mg QD) + gemcitabine (1000 mg/m2)
Study: 21791058
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg QD) + motesanib (100 or 125 mg QD)